Glenmark launches biosimilar Adalimumab in India

Glenmark did not give any financial detail for the drug, but globally Adalimumab is estimated to be a $16 billion drug in 2016, making it the "best" selling drug in the world.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news